Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.40 |
| ▸ | MTOR | P42345 | 14/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719441 | 0.93 | ABL1 (0.39) | PIK3CAMTORMCHR1ATRMCHR2 | |
| SCHEMBL1719285 | 0.91 | SLC6A7 (0.40) | PIK3CAMTORHRH3MCHR1ATR | |
| SCHEMBL1724292 | 0.91 | MCHR1 (0.38) | HRH3MCHR1MCHR2L3MBTL3L3MBTL1 | |
| SCHEMBL1719200 | 0.90 | MCHR1 (0.39) | HRH3MCHR1MCHR2L3MBTL3L3MBTL1 | |
| SCHEMBL1719458 | 0.87 | L3MBTL3 (0.39) | MCHR1MCHR2L3MBTL3L3MBTL1 | |
| SCHEMBL1720060 | 0.87 | MCHR1 (0.39) | PIK3CAMTORMCHR1MCHR2L3MBTL3 | |
| SCHEMBL1719037 | 0.87 | CYP2C9 (0.46) | L3MBTL3L3MBTL1 | |
| SCHEMBL1719366 | 0.86 | PIK3CD (0.42) | HRH3MCHR1MCHR2L3MBTL3L3MBTL1 | |
| SCHEMBL1719224 | 0.85 | MCHR1 (0.39) | HRH3MCHR1MCHR2L3MBTL3L3MBTL1 | |
| SCHEMBL1719410 | 0.84 | HTR2B (0.40) | MCHR1MCHR2L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101687844-B | Imidazole derivatives as CCR2 receptor antagonists | HOFFMANN LA ROCHE | 2013-11-13 | — | — | CN | claimed |
| EP-2173735-B1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-01-11 | — | — | EP | claimed |
| US-7935707-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | claimed |
| US-20090012063-A1 | Novel imidazole derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-08 | — | — | US | claimed |
| CN-101687844-B | Imidazole derivatives as CCR2 receptor antagonists | HOFFMANN LA ROCHE | 2013-11-13 | — | — | CN | disclosed |
| EP-2173735-B1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-01-11 | — | — | EP | disclosed |
| EP-2173735-B1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-7935707-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935707-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935707-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090012063-A1 | Novel imidazole derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012063-A1 | Novel imidazole derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012063-A1 | Novel imidazole derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2009003861-A1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012063-A1 | Novel imidazole derivatives | CCR2, CCR1, CCR3 | PIK3CA 4222/4885MTOR 4145/4885HRH3 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.